Biogen
BIIB
923 hedge funds and large institutions have $58.4B invested in Biogen in 2015 Q3 according to their latest regulatory filings, with 105 funds opening new positions, 407 increasing their positions, 283 reducing their positions, and 150 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 407 | Existing positions reduced: 283
5% less funds holding
Funds holding: 973 → 923 (-50)
29% less funds holding in top 10
Funds holding in top 10: 52 → 37 (-15)
30% less first-time investments, than exits
New positions opened: 105 | Existing positions closed: 150
32% less capital invested
Capital invested by funds: $85.3B → $58.4B (-$26.9B)
32% less call options, than puts
Call options by funds: $1.22B | Put options by funds: $1.8B
Top Buyers
Top Sellers
BIIB Hedge Fund Activity: Q3 2015 in Review
923 of the 3,581 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2015, worth a combined $58.4B — down 32% from $85.3B a quarter earlier.
Sellers outnumbered buyers: 150 funds closed out of BIIB and 105 opened new positions — a net loss of 45 holders — while 283 trimmed existing stakes and 407 added.
The largest buyer was Ameriprise, adding an estimated $395M. The largest seller was Fidelity Investments, cutting an estimated $1.71B.
- 923 institutional investors held Biogen (BIIB) as of Q3 2015, down from 973 in Q2 2015.
- Funds reported $58.4B of Biogen stock for Q3 2015, down 32% quarter-over-quarter.
- 105 funds opened new Biogen positions in Q3 2015 and 150 closed out, a net change of -45 holders.
- The largest Biogen buyer in Q3 2015 was Ameriprise, an estimated $395M added.
- The largest Biogen seller in Q3 2015 was Fidelity Investments, an estimated $1.71B sold.
Based on aggregated 13F filings for Q3 2015.